ABSTRACT
BACKGROUND: First- and third-generation retinoids are the main treatment for acne. Even though efficacious, they lack full selectivity for retinoic acid receptor (RAR) γ, expressed in the epidermis and infundibulum. OBJECTIVES: To characterize the in vitro metabolism and the pharmacology of the novel retinoid trifarotene. MATERIALS AND METHODS: In vitro assays determined efficacy, potency and selectivity on RARs, as well as the activity on the expression of retinoid target genes in human keratinocytes and ex vivo cultured skin. In vivo studies investigated topical comedolytic, anti-inflammatory and depigmenting properties. The trifarotene-induced gene expression profile was investigated in nonlesional skin of patients with acne and compared with ex vivo and in vivo models. Finally, the metabolic stability in human keratinocytes and hepatic microsomes was established. RESULTS: Trifarotene is a selective RARγ agonist with > 20-fold selectivity over RARα and RARß. Trifarotene is active and stable in keratinocytes but rapidly metabolized by human hepatic microsomes, predicting improved safety. In vivo, trifarotene 0·01% applied topically is highly comedolytic and has anti-inflammatory and antipigmenting properties. Gene expression studies indicated potent activation of known retinoid-modulated processes (epidermal differentiation, proliferation, stress response, retinoic acid metabolism) and novel pathways (proteolysis, transport/skin hydration, cell adhesion) in ex vivo and in vivo models, as well as in human skin after 4 weeks of topical application of trifarotene 0·005% cream. CONCLUSIONS: Based on its RARγ selectivity, rapid degradation in human hepatic microsomes and pharmacological properties including potent modulation of epidermal processes, topical treatment with trifarotene could result in good efficacy and may present a favourable safety profile in acne and ichthyotic disorders.
Subject(s)
Acne Vulgaris/drug therapy , Dermatologic Agents/pharmacology , Receptors, Retinoic Acid/agonists , Retinoids/pharmacology , Acne Vulgaris/pathology , Administration, Cutaneous , Animals , Biopsy , Cell Differentiation/drug effects , Cell Line , Dermatologic Agents/therapeutic use , Disease Models, Animal , Drug Evaluation, Preclinical , Drug Stability , Gene Expression/drug effects , Gene Expression Profiling , Humans , Keratinocytes/drug effects , Keratinocytes/metabolism , Mice , Microsomes, Liver , Retinoids/therapeutic use , Skin , Skin Pigmentation/drug effects , Tissue Culture Techniques , Retinoic Acid Receptor gammaABSTRACT
A novel series of novobiocin analogues has been synthesised by removing the lipophilic aryl chain in novobiocin and introducing an amino substituent. The structural modifications have been dictated by the control of lipophilicity and the dissociation constant of the resulting compounds. Antibacterial activity of the new coumarin derivatives could be correlated with the amount of uncharged form in physiological conditions.
Subject(s)
Anti-Bacterial Agents/chemical synthesis , Novobiocin/chemical synthesis , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Coumarins/chemistry , Microbial Sensitivity Tests , Novobiocin/analogs & derivatives , Novobiocin/chemistry , Novobiocin/pharmacology , Staphylococcus aureus/drug effectsABSTRACT
O-beta-D-ribofuranosyl nucleoside I is the minimal structural entity of liposidomycins that maintains enzyme inhibitory activity on MraY. A set of compounds with hydroxyl patterns different from I has been synthesized. The presence of a hydroxyl group in the 3" position is essential for the activity. The 3'-deoxy derivative (IV), however, shows a 5-fold improved potency.
Subject(s)
Aminoglycosides , Anti-Bacterial Agents/chemical synthesis , Bacterial Proteins/antagonists & inhibitors , Transferases , Anti-Bacterial Agents/pharmacology , Structure-Activity Relationship , Transferases (Other Substituted Phosphate Groups)ABSTRACT
Tunicamycins (TCMs) and liposidomycins (LPMs) are naturally occurring inhibitors of the bacterial translocase (MraY). Based on structure-activity relationship (SAR) studies, a molecular model has been proposed for their inhibitory mechanism. This study points out the importance of the nucleoside moiety of liposidomycins in the inhibition of MraY. A simplified molecule (I) based on the liposidomycin core structure has been synthesised and tested on MraY. The compound displayed a moderate inhibitory activity (IC50 = 50 microM). The validation of the molecular model was then performed by synthesising higher homologues of I, containing an additional stereocentre in the 5' position (XIV and XV). In agreement with the prediction, only the (S) isomer XV showed significant activity against MraY (IC50 = 5 microM).
Subject(s)
Aminoglycosides , Anti-Bacterial Agents/chemistry , Bacterial Proteins/antagonists & inhibitors , Enzyme Inhibitors/chemistry , Transferases/antagonists & inhibitors , Uridine/chemistry , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/pharmacology , Bacillus subtilis/enzymology , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Models, Molecular , Molecular Structure , Structure-Activity Relationship , Transferases (Other Substituted Phosphate Groups) , Uridine/chemical synthesisABSTRACT
The macrolide antibiotic erythromycin and its 6-O-methyl derivative (clarithromycin) bind to bacterial ribosomes primarily through interactions with nucleotides in domains II and V of 23S rRNA. The domain II interaction occurs between nucleotide A752 and the macrolide 3-cladinose moiety. Removal of the cladinose, and substitution of a 3-keto group (forming the ketolide RU 56006), results in loss of the A752 interaction and an approximately 100-fold drop in drug binding affinity. Within domain V, the key determinant of drug binding is nucleotide A2058 and substitution of G at this position is the major cause of drug resistance in some clinical pathogens. The 2058G mutation disrupts the drug-domain V contact and leads to a further > 25 000-fold decrease in the binding of RU 56006. Drug binding to resistant ribosomes can be improved over 3000-fold by forming an alternative and more effective contact to A752 via alkyl-aryl groups linked to a carbamate at the drug 11/12 position (in the ketolide antibiotics HMR 3647 and HMR 3004). The data indicate that simultaneous drug interactions with domains II and V strengthen binding and that the domain II contact is of particular importance to achieve binding to the ribosomes of resistant pathogens in which the domain V interaction is perturbed.
Subject(s)
Anti-Bacterial Agents/pharmacology , Erythromycin/analogs & derivatives , Ketolides , Macrolides , Protein Synthesis Inhibitors/pharmacology , RNA, Ribosomal, 23S/drug effects , Ribosomes/drug effects , Base Sequence , Binding Sites , Clarithromycin/pharmacology , Drug Interactions , Drug Resistance, Microbial , Escherichia coli/drug effects , Microbial Sensitivity Tests , Molecular Sequence Data , Mutation , RNA, Ribosomal, 23S/genetics , Ribosomes/geneticsABSTRACT
The synthesis and biological profile in vitro of a series of coumarin inhibitors of gyrase B bearing a N-propargyloxycarbamate at C-3' of noviose is presented. Replacement of the 5-methylpyrrole-2-carboxylate of coumarin drugs with an N-propargyloxycarbamate bioisostere leads to analogues with improved antibacterial activity. Analysis of crystal structures of coumarin antibiotics with the 24 kDa N-terminal domain of the gyrase B protein provides a rational for the excellent inhibitory potency of C-3' N-alkoxycarbamates.
Subject(s)
Carbamates/chemical synthesis , Coumarins/chemical synthesis , Enzyme Inhibitors/chemical synthesis , Pyrroles/chemistry , Topoisomerase II Inhibitors , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/pharmacology , Carbamates/pharmacology , Coumarins/pharmacology , DNA Gyrase , DNA, Superhelical/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Escherichia coli/drug effects , Microbial Sensitivity Tests , Staphylococcus aureus/drug effects , StereoisomerismABSTRACT
Two series of aminosubstituted coumarins were synthesised and evaluated in vitro as inhibitors of DNA gyrase and as potential antibacterials. Novel novobiocin-like coumarins, 4-(dialkylamino)methylcoumarins and 4-((2-alkylamino)ethoxy)coumarins, were discovered as gyrase B inhibitors with promising antibacterial activity in vitro.
Subject(s)
Coumarins/chemical synthesis , Topoisomerase II Inhibitors , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/pharmacology , Coumarins/pharmacology , DNA Gyrase , DNA, Superhelical/metabolism , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Escherichia coli/enzymology , Gram-Positive Bacteria/drug effects , Molecular Structure , Novobiocin/analogs & derivatives , Novobiocin/pharmacology , Peptides, Cyclic/pharmacology , Structure-Activity RelationshipABSTRACT
A series of novobiocin-like coumarincarboxylic acids has been prepared bearing the L-rhamnosyl moiety as the sugar portion of the molecule. The similar DNA gyrase inhibitory activity of the novel class of coumarins to that of novobiocin demonstrates that L-rhamnose can effectively replace L-noviose. Introduction of alkyl side-chains at C-5 of coumarin leads to improved in vitro antibacterial properties in the novel series.
Subject(s)
Coumarins/chemical synthesis , Topoisomerase II Inhibitors , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/pharmacology , Carboxylic Acids/chemical synthesis , Carboxylic Acids/pharmacology , Coumarins/pharmacology , DNA Gyrase , DNA, Superhelical/metabolism , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Escherichia coli/enzymology , Molecular Structure , Novobiocin/analogs & derivatives , Novobiocin/pharmacology , Rhamnose/analogs & derivativesABSTRACT
The design, synthesis, and in vitro biological activity of a series of novel coumarin inhibitors of gyrase B is presented. Replacement of the 3-acylamino residue (3-NHCOR) of coumarin drugs with reversed isosteres C(=O)R, C(=N-OR)R', COOR, CONHR and CONHOR leads to highly potent analogues which displayed excellent inhibition of the negative supercoiling of the relaxed DNA and antibacterial activity.
Subject(s)
Coumarins/chemistry , Coumarins/pharmacology , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Topoisomerase II Inhibitors , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/pharmacology , DNA Gyrase , Drug Design , Enterococcus/drug effects , Escherichia coli/enzymology , Inhibitory Concentration 50 , Methicillin Resistance , Microbial Sensitivity Tests , Novobiocin/analogs & derivatives , Novobiocin/chemistry , Novobiocin/pharmacology , Staphylococcus/drug effects , Structure-Activity RelationshipABSTRACT
The macrolide antibiotic erythromycin interacts with bacterial 23S ribosomal RNA (rRNA) making contacts that are limited to hairpin 35 in domain II of the rRNA and to the peptidyl transferase loop in domain V. These two regions are probably folded close together in the 23S rRNA tertiary structure and form a binding pocket for macrolides and other drug types. Erythromycin has been derivatized by replacing the L-cladinose moiety at position 3 by a keto group (forming the ketolide antibiotics) and by an alkyl-aryl extension at positions 11/12 of the lactone ring. All the drugs footprint identically within the peptidyl transferase loop, giving protection against chemical modification at A2058, A2059 and G2505, and enhancing the accessibility of A2062. However, the ketolide derivatives bind to ribosomes with widely varying affinities compared with erythromycin. This variation correlates with differences in the hairpin 35 footprints. Erythromycin enhances the modification at position A752. Removal of cladinose lowers drug binding 70-fold, with concomitant loss of the A752 footprint. However, the 11/12 extension strengthens binding 10-fold, and position A752 becomes protected. These findings indicate how drug derivatization can improve the inhibition of bacteria that have macrolide resistance conferred by changes in the peptidyl transferase loop.
Subject(s)
Anti-Bacterial Agents/metabolism , Ketolides , Macrolides , Nucleic Acid Conformation , RNA, Ribosomal, 23S/chemistry , RNA, Ribosomal, 23S/metabolism , Anti-Bacterial Agents/chemistry , Base Sequence , Binding Sites , Cell Division , Erythromycin/chemistry , Erythromycin/metabolism , Escherichia coli/drug effects , Escherichia coli/growth & development , Molecular Sequence DataABSTRACT
Ketolides represent a new generation of macrolide antibiotics. In order to identify the ketolide-binding site on the ribosome, a library of Escherichia coli clones, transformed with a plasmid carrying randomly mutagenized rRNA operon, was screened for mutants exhibiting resistance to the ketolide HMR3647. Sequencing of the plasmid isolated from one of the resistant clones and fragment exchange demonstrated that a single U754A mutation in hairpin 35 of domain II of the E. coli 23S rRNA was sufficient to confer resistance to low concentrations of the ketolide. The same mutation also conferred erythromycin resistance. Both the ketolide and erythromycin protected A2058 and A2059 in domain V of 23S rRNA from modification with dimethyl sulphate, whereas, in domain II, the ketolide protected, while erythromycin enhanced, modification of A752 in the loop of the hairpin 35. Thus, mutational and footprinting results strongly suggest that the hairpin 35 constitutes part of the macrolide binding site on the ribosome. Strong interaction of ketolides with the hairpin 35 in 23S rRNA may account for the high activity of ketolides against erythromycin-resistant strains containing rRNA methylated at A2058. The existence of macrolide resistance mutations in the central loop of domain V and in hairpin 35 in domain II together with antibiotic footprinting data suggest that these rRNA segments may be in close proximity in the ribosome and that hairpin 35 may be a constituent part of the ribosomal peptidyl transferase centre.
Subject(s)
Anti-Bacterial Agents/pharmacology , Ketolides , Macrolides , Mutation , Peptidyl Transferases/metabolism , RNA, Ribosomal, 23S/metabolism , Base Sequence , Binding Sites , Drug Resistance, Microbial , Erythromycin , Escherichia coli/drug effects , Escherichia coli/genetics , Molecular Sequence Data , Nucleic Acid Conformation , RNA, Ribosomal, 23S/chemistry , RibosomesABSTRACT
Damnacanthal, an anthraquinone isolated from a plant extract, was found to be a potent, selective inhibitor of p56lck tyrosine kinase activity. The structure, potency, and selectivity of damnacanthal were confirmed by independent synthesis and testing. Damnacanthal exhibited an IC50 of 17 nM for inhibition of p56lck autophosphorylation and an IC50 of 620 nM for phosphorylation of an exogenous peptide by p56lck. Damnacanthal had > 100-fold selectivity for p56lck over the serine/threonine kinases, protein kinase A and protein kinase C, and > 40-fold selectivity for p56lck over four receptor tyrosine kinases. It also demonstrated modest (7-20-fold), but highly statistically significant, selectivity for p56lck over the homologous enzymes p60src and p59fyn. Mechanistic studies demonstrated that damnacanthal was competitive with the peptide binding site, but mixed noncompetitive with the ATP site. Although damnacanthal contains a potentially reactive aldehyde moiety, equilibrium dialysis experiments demonstrated that significant amine formation between damnacanthal and amines occurred only at high concentrations of reactants. However, damnacanthal appeared to bind nonspecifically to membrane lipids and was not active in whole cell tyrosine kinase assays. Damnacanthal is the most potent, selective inhibitor of p56lck tyrosine kinase activity described to date and may represent the starting point for the identification of novel, selective inhibitors of p56lck which are active in whole cell as well as in cell-free systems.
Subject(s)
Anthraquinones/pharmacology , Enzyme Inhibitors/pharmacology , src-Family Kinases/antagonists & inhibitors , Alkaloids/pharmacology , Anthraquinones/chemical synthesis , Anthraquinones/metabolism , Dose-Response Relationship, Drug , Kinetics , Lipids/pharmacology , Lymphocyte Specific Protein Tyrosine Kinase p56(lck) , Peptides/metabolism , Phosphorylation/drug effects , Polylysine/metabolism , Protein Serine-Threonine Kinases/drug effects , Protein-Tyrosine Kinases/drug effects , Ribonuclease, Pancreatic/metabolism , Staurosporine , src-Family Kinases/metabolismABSTRACT
This work tempts to emphasize the relation between the quality of the reception of the young child and the shared observation work done by the team. It also tries to define the psychologist's contribution.
Subject(s)
Anxiety, Separation/psychology , Child Behavior Disorders/psychology , Child Day Care Centers , Psychology, Child , Role , Anxiety, Separation/prevention & control , Child Behavior Disorders/prevention & control , Female , Health Services Needs and Demand , Humans , Infant , Male , Patient Care TeamABSTRACT
A new p56lck tyrosine kinase inhibitor WIN 61651 [1,4-dihydro-7-(4-methyl-1-piperizinyl)-1-(4-(4-methyl-1-piperi zinyl))phenyl- 4-oxo-3-quinolinecarboxamide) is described. WIN 61651, which is competitive with ATP, demonstrates selectivity for the lymphoid restricted tyrosine kinase p56lck over serine/threonine kinases, such as protein kinase C and protein kinase A, and over some other tyrosine kinases, including erbB2, epidermal growth factor receptor, and insulin receptor; however, it is equipotent for inhibition of p56lck and the platelet derived growth factor receptor tyrosine kinases. WIN 61651 inhibits p56lck activity in cell-free assays, tyrosine kinase activity in a T lymphocytic cell line, and T cell activation, as measured by IL-2 production by purified CD4 positive peripheral blood T lymphocytes and the mixed lymphocyte reaction. WIN 61651 constitutes a new tool for studies on the role for tyrosine kinases in lymphocyte function.
Subject(s)
Enzyme Inhibitors/pharmacology , Piperazines/pharmacology , Quinolines/pharmacology , T-Lymphocytes/drug effects , T-Lymphocytes/enzymology , src-Family Kinases/antagonists & inhibitors , Antibodies/pharmacology , CD3 Complex/immunology , CD4 Antigens/immunology , Cells, Cultured , Humans , Kinetics , Lymphocyte Specific Protein Tyrosine Kinase p56(lck) , Phosphorylation , T-Lymphocytes/physiology , Tyrosine/metabolismABSTRACT
Cefpodoxime proxetil (RU 51807) is an enterally absorbed ester prodrug which is rapidly cleaved in vivo after oral administration, with release of the active free acid metabolite cefpodoxime. The in vitro antibacterial activity of the sodium salt of cefpodoxime (RU 51746) against approximately 800 clinical isolates was evaluated comparatively with other orally active beta-lactams. RU 51746 was found to be active against enterobacteria normally susceptible to third generation cephalosporins, with MIC50 values ranging from 0.02 mg/l (Providencia sp) to 5 mg/l (C. freundii). RU 51746 was also active against H. influenzae, including beta-lactamase producing strains (MIC50 0.04 mg/l), oxa-S S. aureus (2,5), beta-hemolytic streptococci (0.05) and S. pneumoniae (0.002). Oxa-R staphylococci and P. aeruginosa were resistant to RU 51746 (MIC50 greater than 40 mg/l for both organisms). The antibacterial activity of RU 51746 was bactericidal in nature and independent from test conditions. The molecule was stable to all the beta-lactamases studied, with the exception of cefuroximase (type Ic). RU 51746 exhibited no strong inhibitory effects on these enzymes, except with Enterobacter P99 (type Ia). A good correlation was found between in vivo activity of RU 51807 and in vitro activity of RU 51746. Cefpodoxime proxetil was found to be more effective than cefaclor in mice with experimental septicemia caused by various streptococci, with a DP50 ratio in the 10-100 range. This advantage was again evidenced for septicemias due to various enterobacteria. In contrast, cefaclor proved more effective in experimental staphylococcus infections. In mice with experimental pneumonia, cefpodoxime proxetil caused sharp falls in K. pneumoniae lung counts. Six days after induction of the infection, 60% of animals under cefpodoxime proxetil had sterile lungs, versus 25% of animals under amoxicillin.